Development of a next-generation endogenous OCT4 inducer and its anti-aging effect in vivo.


Journal

European journal of medicinal chemistry
ISSN: 1768-3254
Titre abrégé: Eur J Med Chem
Pays: France
ID NLM: 0420510

Informations de publication

Date de publication:
05 Sep 2023
Historique:
received: 24 03 2023
revised: 05 05 2023
accepted: 23 05 2023
medline: 19 6 2023
pubmed: 31 5 2023
entrez: 30 5 2023
Statut: ppublish

Résumé

The identification of small molecules capable of replacing transcription factors has been a longstanding challenge in the generation of human chemically induced pluripotent stem cells (iPSCs). Recent studies have shown that ectopic expression of OCT4, one of the master pluripotency regulators, compromised the developmental potential of resulting iPSCs, This highlights the importance of finding endogenous OCT4 inducers for the generation of clinical-grade human iPSCs. Through a cell-based high throughput screen, we have discovered several new OCT4-inducing compounds (O4Is). In this work, we prepared metabolically stable analogues, including O4I4, which activate endogenous OCT4 and associated signaling pathways in various cell lines. By combining these with a transcription factor cocktail consisting of SOX2, KLF4, MYC, and LIN28 (referred to as "CSKML") we achieved to reprogram human fibroblasts into a stable and authentic pluripotent state without the need for exogenous OCT4. In Caenorhabditis elegans and Drosophila, O4I4 extends lifespan, suggesting the potential application of OCT4-inducing compounds in regenerative medicine and rejuvenation therapy.

Identifiants

pubmed: 37253308
pii: S0223-5234(23)00479-8
doi: 10.1016/j.ejmech.2023.115513
pii:
doi:

Substances chimiques

Kruppel-Like Factor 4 0
Transcription Factors 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

115513

Informations de copyright

Copyright © 2023 Elsevier Masson SAS. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Han Kang (H)

Institute of Pharmacy and Molecular Biotechnology, Heidelberg University, Germany.

Sebastian Hasselbeck (S)

Buchmann Institute for Molecular Life Sciences, Goethe University Frankfurt am Main, Germany.

Katerina Taškova (K)

Faculty of Biology, Johannes Gutenberg University Mainz, Germany.

Nessa Wang (N)

Institute of Pharmacy and Molecular Biotechnology, Heidelberg University, Germany.

Luuk N van Oosten (LNV)

Institute of Pharmacy and Molecular Biotechnology, Heidelberg University, Germany.

Ralf Mrowka (R)

Experimentelle Nephrologie, KIM III, Universitätsklinikum, Jena, Germany.

Jochen Utikal (J)

Skin Cancer Unit (G300), German Cancer Research Center (DKFZ), Heidelberg, Germany.

Miguel A Andrade-Navarro (MA)

Faculty of Biology, Johannes Gutenberg University Mainz, Germany.

Jichang Wang (J)

Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.

Stefan Wölfl (S)

Institute of Pharmacy and Molecular Biotechnology, Heidelberg University, Germany.

Xinlai Cheng (X)

Institute of Pharmacy and Molecular Biotechnology, Heidelberg University, Germany; Buchmann Institute for Molecular Life Sciences, Goethe University Frankfurt am Main, Germany; Frankfurt Cancer Institute, Germany. Electronic address: Cheng@pharmchem.uni-frankfurt.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH